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Abstract.This study evaluated the safety of sub-acute administration of Terminalia catappa L. 
aqueous leaf extract (TCA) on cardiac biochemical parameters. Graded concentrations (200, 400 
and 800 mg/kg) of TCA wereorally administered daily for 28 days. Cardiac biochemical 
parameters of toxicity were thereafter accessedusing standard methods forsuperoxide dismutase, 
peroxidase, glutathione-S-transferase, reduced glutathione, lipid peroxidation, protein levels, 
cholesterol, triglyceride, lactate dehydrogenase and creatinine kinase. TCA treatment did not alter 
the heart weight and cardiac biochemical parameters. Nonetheless, at 800 mg/kg, the antioxidant 
profile was significantly improved after TCA treatment. There was no mediated sign of treatment 
toxicityas well asa change in cardiac histological architecture. T. catappaaqueous leaf extract is 
relatively non-toxic to the heart at the experimental doses and also within the test period. 
Keywords:Terminalia catappa L., sub-acute, toxicity, Cardiac, test period 
1. INTRODUCTION 
There is a heavy dependence on traditional medicine by Asian and African populace in the prevention and 
management of various diseases [1]. Accessibility, affordability and cultural acceptance have aided in the 
continuous ethnomedicinal use of numerous medicinal plants by a large part of the population in Nigeria 
to cope with the increasing incidence of chronic diseases and health-care overheads [2]. 
Terminalia catappa Linn (Combretaceae) (TC), is known for its edible fruit and nut. It is found in the 
tropics and widely distributed through the tropics, Asia subtropical regions, Australia and Africa[3]. 
Phytochemicals such as tannins, phenols, flavonoids, alkaloids, triterpenes, coumarins and others have 
been reported to be present in its leaf [4,5]. Anti-cancer, hepatoprotective, anti-HIV reverse transcriptase, 
anti-hepatitis, anti-inflammatory and aphrodisiac effects are some of the reported pharmacological 
activity present in various extracts of the leaves[6,7]. TC is employed by local medicine men in 
Southwest Nigeria as a general tonic to treat ailments such as wounds, haemorrhages, cardiovascular 
diseases and heart disorders [3]. In urban areas where TC is found, its leaves constitute a major part of 
metropolitan lignocellulosic waste. Various preparations of leaves are administered without any prior 
knowledge of their safe levels and cardio-toxic effect of long term consumption. The present study 
evaluated the consequence of sub-acute oral administration of T. catappa aqueous leaf extract on cardiac 
biochemical parameters. 
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2. MATERIALS AND METHOD 
All chemicals and reagents acquired from Burguboyne, Sigma Aldrichand AnalR were of analytical 
grade.  
2.1. Collection and Identification of Sample 
Healthy T. catappa leaves were obtained from Covenant University and identified by Dr. J.O. Popoola 
from the Department of Biological Sciences, Covenant University. A voucher specimen was deposited in 
the herbarium with voucher number TC/CUBio/H809 and ascension code OgCuNo809.  
2.2. Extract Preparations  
The aqueous crude extract (TCA) was prepared as reported by Iheagwam et al.[8] with slight 
modification. Briefly, the leaves were washed, air dried at room temperature for two (2) weeks and 
crushed to a uniform size. Sample blend (500 g) was steeped in distilled water (10 L) for 72 h with 
periodical stirring. The obtained filtrate was concentrated using a rotary evaporator (Stuart, RE 300/MS, 
Staffordshire, UK) to yield an aqueous crude extract. 
2.3. Experimental Animals  
Adult male albino Wistar rats (n = 20) presumed to be healthy were purchased from the National Institute 
of Medical Research (NIMR), Lagos, Nigeria and housed in the Department of Biochemistry animal 
house in Covenant University. They were maintained with an alternating 12 hrs light and dark cycle, 
access to food and water ad libitum prior to and during the experimental period.The guidelines for the 
care and use of laboratory animals documented by the National Institute of Health for the Care and Use of 
Laboratory Animals was strictly adhered to. An approval (CHREC/031/2018) was granted by Covenant 
University Health, Research and Ethics Committee. 
2.4. Sub-acute Toxicity Assessment Protocol 
Rats (n = 20) were randomly divided into 4 groups (n=5) as projectedin Table 1: 
Table 1: Sub-acute assessment experimental design 
GROUPS TREATMENT Rat No. 
Group I Normal rats treated with vehicle alone 5 
Group II Rats treated with 200 mg/kg bwt of TCA 5 
Group III Rats treated with 400 mg/kg bwt of TCA 5 
Group IV Rats treated with 800 mg/kg bwt of TCA 5 
Sub-acute toxicity was done according to the Organization for Economic Cooperation and Development 
(OECD) guidelines 423 as described by Ogunlana et al.[9]. Plant extract and vehicle wereorally 
administered for 28 days and animals monitored for signs of toxicity. On the 28th day, after 12 h fasting, 
the rats were anaesthetizedusing a single dose combination of xylazine and ketamine (5 and 50 mg/kg, i.p 
respectively) and sacrificed by cardiac puncture.Blood collected was poured into heparin tubes while the 
heart was collected, rinsed with normal saline, dried and stored in -20oC freezer (Haier Thermocool, BD-
719R6) until analysis. A sizeable portion of cardiac tissue was stored in 10% neutral buffered formalin for 
histopathological assessment. Plasma was obtained from whole blood by centrifugation at 4000 rpm for 5 
mins. Homogenate was obtained from a portion of the heart, homogenized in ice-cold homogenization 
buffer pH 7.2 using a Teflon pestle homogenizer and centrifuged at 10, 000 rpm for 15 min. The retrieved 
samples were stored at 4 oC and used for biochemical analysis. 
2.5. Biochemical Analysis  
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The levels of superoxide dismutase (SOD) [10], peroxidase (Px) [11], glutathione-S-transferase (GST) 
[12], reduced glutathione (GSH) [13], lipid peroxidation (LPO) [14] and protein levels (TP) [15] were 
analysed in the heart according to standard procedures and methods at the end of the experimental period.  
Cardiac cholesterol (CHOL), cardiac triglyceride (TG), plasma lactate dehydrogenase (LDH) and plasma 
creatinine kinase (CK) activities were analyzed according to procedures described in the commercial kits 
(Randox Lab., England, UK). 
2.6. Histopathological Analysis 
Histopathological assessment of cardiac tissues was adopted as reported by Chinedu et al.[16]. 
2.7. Statistical Analysis  
Values were analysed using one-way analysis of variance (ANOVA) supplemented with Duncan post-hoc 
analysis using IBM SPSS Statistics 23 (IBM Corp., New York, USA). All results were reported as mean 
± standard error of mean (SEM) of five (5) replicates and, considered statistically significant at p<0.05. 
3. RESULTS 
All treatment groups administered with various concentration (200 – 800 mg/kg) of the extract survived 
the experimental duration as no toxic sign was observed compared with the control group.Figure 1 depicts 
the effect of TCA on relative heart weight. In comparison with the control group, daily TCA 
administration did not alter the relative weight of the heart (p<0.05). 
 
Figure 1: Effect of TCA on relative cardiac weight. Bars are represented as mean ± SEM (n=5).  
Table 2 shows the response of various cardiac antioxidant parameters after 28-day sub-acute TCA 
treatment. Daily TCA treatment significantly (p<0.05) increased GSH concentration as well as the 
activities of SOD and GST when compared with the control group. However, only the group administered 
with the highest dose (800 mg/kg) was able to significantly (p<0.05) increase Px activity with a 
concomitant significant (p<0.05) decrease in LPO concentration compared with the control. 
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Table 2: Effect of TCA on cardiac antioxidant parameters (per mg protein) 
 Control 200 mg/kg 400 mg/kg 800 mg/kg 
SOD (Units) 297.84 ± 39.15a 390.37 ± 66.58b 316.70 ± 55.61a 463.46 ± 41.18b 
Px (Units) 17.81 ± 2.36a 18.31 ± 2.22a 21.05 ± 1.15a 32.67 ± 1.96b 
GST (Units) 122.26 ± 11.46a 139.71 ± 6.64b 153.52 ± 14.39b 177.14 ± 15.62c 
GSH (nM) 33.60 ± 4.08a 45.20 ± 4.18b 41.40 ± 4.41b 69.40 ± 4.81c 
LPO (µM) 4.86 ± 0.91a 4.19 ± 1.09a 3.55 ± 0.96a 2.55 ± 0.75b 
Values are represented as mean ± SEM (n=5). Data with different superscripts across a row are 
significantly different at p<0.05. Abbreviations: SOD - superoxide dismutase; Px - peroxidase; GST - 
glutathione-S-transferase; GSH - reduced glutathione; LPO - lipid peroxidation. 
The effect of sub-acute administration of TCA on some biochemical parameters is represented in table 3. 
No significant change was observed in the concentration of cardiac CHOL, TG and TP in both the 
experimental and control group. The same observation was made in the activity of CK and LDH in the 
plasma between the control and administered groups (Figure 2). There was no significant change in the 
histological architecture of the heart of both experimental and control rats (Figure 3). 
Table 3: Effect of TCA on some cardiac biochemical parameters 
 Control 200 mg/kg 400 mg/kg 800 mg/kg 
CHOL (mg/dL) 24.64 ± 7.42 23.89 ± 5.28 22.77 ± 10.37 26.54 ± 8.35 
TG (mg/dL) 122.65 ± 34.69 131.12 ± 41.35 126.28 ± 27.63 119.90 ± 30.44 
TP (mg/mL) 51.50 ± 0.92 55.17 ± 0.83 53.13 ± 1.34 55.27 ± 2.25 
Values are represented as mean ± SEM (n=5). Abbreviations: CHOL - cholesterol;TG - triglyceride;TP - 
protein levels.  
 
Figure 2: Activity of some heart function parameters after 28-day TCA treatment. Bars are represented as 
mean ± SEM (n=5). Abbreviations: LDH - lactate dehydrogenase; CK - creatinine kinase.  
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(a)  (b)  
(c)  (d)  
Figure 3: Histological sections from ratcardiac tissuesof groups treated with (a) control (b) 200 mg/kg (c) 
400 mg/kg (d) 800 mg/kg TCA. Photomicrographsreveals bundles of myocardial fibres, interstitial space 
and coronary artery (HE. 100X). 
4. DISCUSSION AND CONCLUSION  
In this study, there were no clinical signs of morbidity, toxicity or mortality after sub-acute daily dose 
treatment with TCA. It can be deduced that TCA is relatively non-cardio-toxic at the experimental dose 
and time frame. Relative organ weight index is important in determining the toxicity of various 
compounds in experimental animals [17]. SOD and Px are first-linedefence mechanisms against reactive 
oxygen species (ROS) under physiological and pathological condition thus, novel drugs mimicking their 
mechanism of action are used in the treatment of diseases associated with ROS [18]. GST is a phase 2 
enzyme used to conjugate phase 1 activated toxic intermediates to ensure they are more polar and easily 
excreted. They exert this antioxidant property by transferring glutathione to these intermediates. For 
cardiac markers of oxidative stress, the significant decrease in lipid peroxidation of animals treated with 
800 mg/kg indicates that malondialdehyde concentration was reduced. This alteration was compensated 
by the increase in GSH concentration, SOD, GST and Px activity, reducing the peroxidation of the 
cardiac lipid membrane. This indicates that TCA treatment helps maintain the antioxidant/oxidant system 
homeostasis [19]. Biochemical parameters alterationsare effective pointers of organ damage and 
dysfunction. Since there was no alteration in the relative cardiac weight.It is a strong indicator that TCA 
may not have any adverse effect and/or toxicity on the heart. It is noteworthy, that inflammation and 
increased secretion by the organ is correlated with an increase in organ weight while a reduction could 
suggest cellular constriction. LDH and CK are enzymes found in the myocardial cells of the heart.  When 
cardiac toxicity occurs, the integrity of the cardiac membrane is altered, leading to increased cell 
membrane permeability concomitantly increasing serum activity of these enzymes [20]. Analysis of 
plasma CK and LDH activity shown in figure 2 demonstrates that TCA treatment did not promote 
3rd International Conference on Science and Sustainable Development (ICSSD 2019)




significant alterations in these cardiac biomarkers of toxicity. This was further corroborated by 
histological examinations in which there was no pathological change on the cardiac architecture. Hence, 
TCA may not have any cardio-toxic effect thus, expanded cardiac muscle contraction, myocyte death and 
altered membrane permeability which are some hallmarks of cardiac toxicity as reported by El Shaer may 
be absent [21]. This was further verified by Sabiu et al. [22] that unnecrotised myocytes which portrayed 
uniform architectural arrangement, do not have altered cardiac biomarkers of toxicity. TCA 
administration showed no significant variation in the cardiac concentration of CHOL, TG and TP as 
earlier observed for the cardiac enzymes of toxicity. This may indicate that the extract did not alter the 
metabolism of these macromolecules in the heart. Our study reveals T. catappa aqueous leaves extract is 
relatively safe to use in the treatment of heart disorders. It also possesses antioxidant properties and thus 
validates its use in ethnomedicine. Further studies are however required to evaluate the safety of TCA 
administration on other tissues.  
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